The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside
Dimos D Mitsikostas 1 , Christian Waeber 2 3 , Margarita Sanchez-Del-Rio 4 , Bianca Raffaelli 5 6 , Håkan Ashina 6 7 8 , Antoinette Maassen van den Brink 9 , Anna Andreou 10 11 , Patricia Pozo-Rosich 12 13 14 , Alan Rapoport 15 , Messoud Ashina 6 , Michael A Moskowitz 16
Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition.
Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence. After the introduction of agents that target the calcitonin gene-related peptide pathway, another new drug class, the ditans - a group of selective serotonin 5-HT1F receptor agonists - has just reached the international market.
Here, we review preclinical studies from the late 1990s and more recent clinical research that contributed to the development of the ditans and led to their approval for acute migraine treatment by the US Food and Drug Administration and the European Medicines Agency.
CITA DEL ARTÍCULO Nat Rev Neurol. 2023 Jul 12. doi: 10.1038/s41582-023-00842-x